Abstract
Thyroid hormone receptor α1 (TRα1) is shown to be critical for the maturation of cardiomyocytes and for the cellular response to stress. TRα1 is altered during post ischemic cardiac remodeling but the physiological significance of this response is not fully understood. Thus, the present study explored the potential consequences of selective pharmacological inhibition of TRα1 on the mechanical performance of the post-infarcted heart. Acute myocardial infarction was induced in mice (AMI), while sham operated animals served as controls (SHAM). A group of mice was treated with debutyl-dronedarone (DBD), a selective TRα1 inhibitor (AMI–DBD). AMI resulted in low T3 levels in plasma and in down-regulation of TRα1 and TRβ1 expression. Left ventricular ejection fraction (LVEF%) was significantly reduced in AMI [33 (SEM 2.1) vs 79(2.5) in SHAM, p < 0.05] and was further declined in AMI–DBD [22(1.1) vs 33(2.1), respectively, p < 0.05]. Cardiac mass was increased in AMI but not in AMI–DBD hearts, resulting in significant increase in wall tension index. This increase in wall stress was accompanied by marked activation of p38 MAPK, a kinase that is sensitive to mechanical stretch and exerts negative inotropic effect. Furthermore, AMI resulted in β-myosin heavy chain overexpression and reduction in the ratio of SR(Ca)ATPase to phospholamban (PLB). The latter further declined in AMI–DBD mainly due to increased expression of PLB. AMI induces downregulation of thyroid hormone signaling and pharmacological inhibition of TRα1 further depresses post-ischemic cardiac function. p38 MAPK and PLB may, at least in part, be involved in this response.
Similar content being viewed by others
References
De Groot LJ (1999) Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab 84:151–164
Friberg L, Werner S, Eggertsen G, Ahnve S (2002) Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med 162:1388–1394
Lazzeri C, Sori A, Picariello C, Chiostri M, Gensini GF, Valente S (2012) Nonthyroidal illness syndrome in ST-elevation myocardial infarction treated with mechanical revascularization. Int J Cardiol 158:103–104
Lymvaios I, Mourouzis I, Cokkinos DV, Dimopoulos MA, Toumanidis ST, Pantos C (2011) Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association? Eur J Endocrinol 165:107–114
Pantos C, Mourouzis I, Galanopoulos G, Gavra M, Perimenis P, Spanou D, Cokkinos DV (2010) Thyroid hormone receptor alpha1 downregulation in postischemic heart failure progression: the potential role of tissue hypothyroidism. Horm Metab Res 42:718–724
Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM (2008) Short term triiodo-l-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol 44:180–187
Chen YF, Pottala JV, Weltman NY, Ge X, Savinova OV, Gerdes AM (2012) Regulation of gene expression with thyroid hormone in rats with myocardial infarction. PLoS One 7:e40161
Forini F, Lionetti V, Ardehali H, Pucci A, Cecchetti F, Ghanefar M, Nicolini G, Ichikawa Y, Nannipieri M, Recchia FA, Iervasi G (2011) Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodelling in rats. J Cell Mol Med 15:514–524
Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM (2009) Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail 2:243–252
Pantos C, Mourouzis I, Markakis K, Dimopoulos A, Xinaris C, Kokkinos AD, Panagiotou M, Cokkinos DV (2007) Thyroid hormone attenuates cardiac remodelling and improves hemodynamics early after acute myocardial infarction in rats. Eur J Cardiothorac Surg 32:333–339
Pantos C, Mourouzis I, Markakis K, Tsagoulis N, Panagiotou M, Cokkinos DV (2008) Long-term thyroid hormone administration reshapes left ventricular chamber and improves cardiac function after myocardial infarction in rats. Basic Res Cardiol 103:308–318
Pantos C, Mourouzis I, Tsagoulis N, Markakis K, Galanopoulos G, Roukounakis N, Perimenis P, Liappas A, Cokkinos DV (2009) Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J Physiol Pharmacol 60:49–56
Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D (2008) Thyroid hormone and “cardiac metamorphosis”: potential therapeutic implications. Pharmacol Ther 118:277–294
Pantos C, Xinaris C, Mourouzis I, Perimenis P, Politi E, Spanou D, Cokkinos DV (2008) Thyroid hormone receptor alpha1: a switch to cardiac cell “metamorphosis”? J Physiol Pharmacol 59:253–269
Kinugawa K, Jeong MY, Bristow MR, Long CS (2005) Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol 19:1618–1628
Belakavadi M, Saunders J, Weisleder N, Raghava PS, Fondell JD (2010) Repression of cardiac phospholamban gene expression is mediated by thyroid hormone receptor-alpha1 and involves targeted covalent histone modifications. Endocrinology 151:2946–2956
Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Roukounakis N, Kokkinos AD, Cokkinos DV, Pantos C (2011) Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: potential involvement of Akt and ERK signalings. Mol Cell Biochem 363:235–243
Pantos C, Mourouzis I, Malliopoulou V, Paizis I, Tzeis S, Moraitis P, Sfakianoudis K, Varonos DD, Cokkinos DV (2005) Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor alpha1. Thyroid 15:16–23
Van Beeren HC, Jong WM, Kaptein E, Visser TJ, Bakker O, Wiersinga WM (2003) Dronerarone acts as a selective inhibitor of 3,5,3′-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology 144:552–558
van Beeren HC, Kwakkel J, Ackermans MT, Wiersinga WM, Fliers E, Boelen A (2012) Action of specific thyroid hormone receptor alpha(1) and beta(1) antagonists in the central and peripheral regulation of thyroid hormone metabolism in the rat. Thyroid 22:1275–1282
Kalofoutis C, Mourouzis I, Galanopoulos G, Dimopoulos A, Perimenis P, Spanou D, Cokkinos DV, Singh J, Pantos C (2010) Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. Mol Cell Biochem 345:161–169
Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn GW 2nd (1998) Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95:10140–10145
van Empel VP, De Windt LJ (2004) Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 63:487–499
Suarez J, Scott BT, Suarez-Ramirez JA, Chavira CV, Dillmann WH (2010) Thyroid hormone inhibits ERK phosphorylation in pressure overload-induced hypertrophied mouse hearts through a receptor-mediated mechanism. Am J Physiol Cell Physiol 299:C1524–C1529
Pantos C, Mourouzis I, Cokkinos DV (2011) New insights into the role of thyroid hormone in cardiac remodelling: time to reconsider? Heart Fail Rev 16:79–96
Pantos C, Mourouzis I, Cokkinos DV (2012) Thyroid hormone and cardiac repair/regeneration: from Prometheus myth to reality? Can J Physiol Pharmacol 90:977–987
Pantos C, Mourouzis I, Saranteas T, Brozou V, Galanopoulos G, Kostopanagiotou G, Cokkinos DV (2011) Acute T3 treatment protects the heart against ischemia-reperfusion injury via TRalpha1 receptor. Mol Cell Biochem 353:235–241
Pantos C, Malliopoulou V, Varonos DD, Cokkinos DV (2004) Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol 99:101–120
Pantos C, Mourouzis I, Cokkinos DV (2010) Thyroid hormone as a therapeutic option for treating ischaemic heart disease: from early reperfusion to late remodelling. Vascul Pharmacol 52:157–165
Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H, Saffitz J, Chien K, Xiao RP, Kass DA, Wang Y (2001) The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA 98:12283–12288
Vahebi S, Ota A, Li M, Warren CM, de Tombe PP, Wang Y, Solaro RJ (2007) p38-MAPK induced dephosphorylation of alpha-tropomyosin is associated with depression of myocardial sarcomeric tension and ATPase activity. Circ Res 100:408–415
Aikawa R, Nagai T, Kudoh S, Zou Y, Tanaka M, Tamura M, Akazawa H, Takano H, Nagai R, Komuro I (2002) Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension 39:233–238
Auger-Messier M, Accornero F, Goonasekera SA, Bueno OF, Lorenz JN, van Berlo JH, Willette RN, Molkentin JD (2012) Unrestrained p38 MAPK activation in Dusp1/4 double null mice induces cardiomyopathy. Circ Res 112(1):48–56
Tavi P, Sjogren M, Lunde PK, Zhang SJ, Abbate F, Vennstrom B, Westerblad H (2005) Impaired Ca2+ handling and contraction in cardiomyocytes from mice with a dominant negative thyroid hormone receptor alpha1. J Mol Cell Cardiol 38:655–663
Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D (2012) Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 110:607–613
Pantos C, Mourouzis I (2011) Comment: worsening heart failure in the setting of dronedarone initiation. Ann Pharmacother 45:689
Acknowledgments
This study was supported by Alexander S. Onassis Foundation and M. Zobanakis.
Conflict of Interest
None declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mourouzis, I., Kostakou, E., Galanopoulos, G. et al. Inhibition of thyroid hormone receptor α1 impairs post-ischemic cardiac performance after myocardial infarction in mice. Mol Cell Biochem 379, 97–105 (2013). https://doi.org/10.1007/s11010-013-1631-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-013-1631-9